Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15030617 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL8083082 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL4752 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL13693410 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL13920783 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL13301231 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL6997217 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL14094837 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL8295172 | 0.83 | FFAR1 (0.70) | HDAC4ALDH1A1SLC9A1SMN1; SMN2HPGD | |
| SCHEMBL4126470 | 0.83 | FFAR1 (0.70) | HDAC4ALDH1A1SLC9A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2927218-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9914702-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2018-03-13 | — | — | US | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | BIONOMICS, LTD (AU) | 2017-03-30 | — | — | US | disclosed |
| US-9493451-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2016-11-15 | — | — | US | disclosed |
| EP-2483251-B1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2742029-B1 | N-(BENZIMIMDAZOL-2-YL)-CYCLOPROPANE CARBOXAMIDES AS LYSOPHOSPHATIDIC ACID ANTAGONISTS | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | ABBVIE INC. | 2005-02-17 | — | — | US | disclosed |
| CN-1168704-C | Aryl and heteroaryl cyclopropyl oximidoether and its application as bactericide and pesticide | 陶氏益农有限责任公司 | 2004-09-29 | — | — | CN | disclosed |
| WO-2004018462-A1 | QUINAZOLINONE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2004-03-04 | — | — | WO | disclosed |
| CN-1479718-A | Aryl and heteroarylcyclopropyl oximie ethers and their use as fungicides | 美国陶氏益农公司 | 2004-03-03 | — | — | CN | disclosed |
| CN-1262269-A | Aryl and heteroaryl cyclopropyl oximidoether and its application as bactericide and pesticide | ROHM & HAAS (US) | 2000-08-09 | — | — | CN | disclosed |
| US-5175183-A | Antiinflammatory agents, respiratory system disorders | ABBOTT LABORATORIES (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0456760-A4 | LIPOXYGENASE INHIBITING COMPOUNDS | — | 1992-01-08 | — | — | EP | disclosed |
| EP-0456760-A1 | LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1991-11-21 | — | — | EP | disclosed |
| WO-1990008545-A1 | LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1990-08-09 | — | — | WO | disclosed |
| US-4328363-A | Manufacture of gamma halogen substituted adducts | MOBIL OIL CORPORATION (US) | 1982-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | KCNA3, KCNH3, KCNK3 | HDAC4 808/4885ALDH1A1 3267/4885SLC9A1 226/4885 |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | PRKAG1, PRKAG3, PRKAG2 | HDAC4 666/4885ALDH1A1 944/4885SLC9A1 4746/4885 |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | RTN3, CYCS, ATL3 | HDAC4 665/4885ALDH1A1 3212/4885SLC9A1 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.